Riskpilot← Back to searchSign inGet full accessKRAGERØ TABLETTPRODUKSJON AS
ASActiveOrg 984857888Kirkegata 15, 3770 KragerøManufacture of pharmaceutical preparations · NACE 2120Est. 20024 employees
Revenue 2024
NOK 33,1M
+15% vs 2023
EBITDA margin
46.8%
-4% vs 2023
Equity ratio
73.8%
Financial strength
Net profit 2024
NOK 12,7M
-2% vs 2023
| Revenue | NOK 33,1M | +15% |
| EBITDA | NOK 15,5M | -4% |
| Net profit | NOK 12,7M | -2% |
| Total assets | NOK 38,7M | -7% |
| Equity | NOK 28,6M | -13% |
| Employees | 4 | — |
Legal name
KRAGERØ TABLETTPRODUKSJON AS
Org number
984857888
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
19. september 2002
Share capital
NOK 102 500
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Drive produksjon og salg av legemidler og andre apotekvarer, samt annen virksomhet som naturlig hører til, herunder deltakelse i andre virksomheter.
Address
Kirkegata 15, 3770 Kragerø
Phone
+4740002155
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 291 | 11 123 | 10 675 | 11 999 | 13 503 | 24 452 | 24 767 | 23 292 | 25 868 | 29 768 | 26 795 | 29 697 | 22 944 | 20 046 | 21 587 | 28 635 | 33 068 |
| Staff expenses | −4 233 | −4 612 | −5 032 | −5 137 | −5 249 | −5 592 | −4 859 | −5 197 | −5 824 | −5 611 | −5 073 | −5 267 | −4 472 | −4 425 | −3 950 | −4 002 | −4 217 |
| EBITDA | 2 066 | 3 089 | 2 199 | 2 880 | 2 947 | 12 365 | 12 505 | 12 809 | 13 252 | 17 405 | 14 577 | 18 122 | 11 582 | 9 956 | 12 337 | 16 217 | 15 490 |
| Depreciation & amort. | −139 | −190 | −257 | −457 | −444 | −454 | −504 | −522 | −484 | −519 | −491 | −320 | −168 | −144 | −64 | −202 | −417 |
| EBIT | 1 927 | 2 899 | 1 943 | 2 423 | 2 503 | 11 910 | 12 002 | 12 287 | 12 768 | 16 886 | 14 086 | 17 801 | 11 414 | 9 812 | 12 273 | 16 015 | 15 073 |
| Net financials | 155 | 51 | −25 | −56 | −39 | 67 | 255 | 306 | 43 | −131 | 209 | 305 | 325 | 90 | 147 | 549 | 1 169 |
| Profit before tax | 2 083 | 2 950 | 1 918 | 2 367 | 2 465 | 11 977 | 12 257 | 12 593 | 12 811 | 16 756 | 14 295 | 18 107 | 11 739 | 9 901 | 12 420 | 16 563 | 16 242 |
| Tax | 586 | 826 | 539 | 663 | 691 | 3 350 | 3 312 | 3 393 | 3 201 | 4 021 | 3 290 | 3 984 | 2 584 | 2 178 | 2 732 | 3 645 | 3 573 |
| Net profit | 1 497 | 2 124 | 1 379 | 1 704 | 1 774 | 8 627 | 8 945 | 9 200 | 9 610 | 12 735 | 11 006 | 14 123 | 9 155 | 7 723 | 9 688 | 12 918 | 12 669 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 405 | 9 226 | 10 852 | 10 628 | 11 106 | 21 825 | 22 465 | 23 088 | 33 053 | 30 934 | 32 025 | 38 678 | 35 633 | 19 049 | 28 401 | 41 544 | 38 737 |
| Equity | 3 772 | 5 896 | 1 741 | 2 695 | 3 970 | 6 597 | 9 542 | 8 742 | 18 351 | 10 086 | 21 092 | 18 301 | 21 152 | 12 365 | 20 935 | 32 662 | 28 577 |
| Long-term debt | 88 | 396 | 0 | 260 | 0 | 2 652 | 144 | 7 089 | 7 067 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 21 |
| Short-term debt | 2 544 | 2 934 | 8 747 | 7 672 | 3 920 | 12 576 | 12 779 | 7 258 | 7 636 | 20 832 | 10 933 | 20 377 | 14 482 | 6 684 | 7 466 | 8 882 | 10 140 |
| Total debt | 2 632 | 3 330 | 9 111 | 7 932 | 7 136 | 15 228 | 12 923 | 14 347 | 14 702 | 20 847 | 10 933 | 20 377 | 14 482 | 6 684 | 7 466 | 8 882 | 10 160 |
EBITDA margin
46.8%
This company
15.8%
Market median
+196% vs market
20082024
Equity ratio
73.8%
This company
38.2%
Market median
+93% vs market
20082024
Return on equity
44.3%
This company
18.4%
Market median
+141% vs market
20082024
Net profit margin
38.3%
This company
8.1%
Market median
+373% vs market
20082024
Asset turnover
0.85×
This company
1.12×
Market median
+24% vs market
20082024
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pharmore As | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharmore As
KRAGERØ TABLETTPRODUKSJON AS Board members of KRAGERØ TABLETTPRODUKSJON AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ragnar Salmen | Chairman | 0 companies |